GeNeuro S.A.
$0.03▲ 0.00%(+$0.00)
TickerSpark Score
28/100
▌ Poor
20
Valuation
30
Profitability
15
Growth
44
Health
30
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNRO.PA research report →
52-Week Range9% of range
Low
$0.02
Current
$0.03
High
$0.15
Company Overviewwww.geneuro.com
About the company
GeNeuro S. A. is a clinical-stage biopharmaceutical entity focused on developing therapies for various neurodegenerative and autoimmune disorders.
- CEO
- Jesus Martin-Garcia
- IPO
- 2016
- Employees
- 17
- HQ
- Plan-les-Ouates, CH
Price Chart
-74.12% · this period
Valuation
- Market Cap
- $911.56K
- P/E
- -0.05
- P/S
- 0.00
- P/B
- -0.06
- EV/EBITDA
- -0.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 239.67%
- ROIC
- -1609.85%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-14,757,000 · -20.96%
- EPS
- $-0.59 · -15.69%
- Op Income
- $-14,357,300
- FCF YoY
- 22.53%
Performance & Tape
- 52W High
- $0.15
- 52W Low
- $0.02
- 50D MA
- $0.03
- 200D MA
- $0.04
- Beta
- 0.66
- Avg Volume
- 154.31K
Get TickerSpark's AI analysis on GNRO.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · GNRO.PA
Our GNRO.PA coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on GNRO.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNRO.PA report →Internal Compare
Similar companies
Peers in the same neighborhood.